US Pediatric Cardiology Market Revenue to cross US$ 3,599.40 Million by 2031

Titanium Implants Segment to Lead US Pediatric Cardiology Market During 2023–2031

According to our new research study on "US Pediatric Cardiology Market Forecast to 2031 – Country Analysis – by Product Type, Surgical Procedure, Disease Indication, and End User," the market size is projected to reach US$ 3,599.40 million by 2031 from US$ 2,541.22 million in 2023. The market is expected to register a CAGR of 4.4%. The market report emphasizes trends prevalent in the market, along with drivers and deterrents affecting its growth. Pediatric cardiology is a specialized branch of medicine that focuses on diagnosing, treating, and managing heart conditions in infants, children, and adolescents. This field addresses a range of congenital (present at birth) and acquired heart defects, including conditions like ventricular septal defects, atrial septal defects, and more complex issues requiring surgical intervention. Surging incidences of congenital heart defects among Pediatrics and growing shift towards minimally invasive procedures are among the prominent factors driving the US pediatric cardiology market growth. However, the limited reimbursements are hampering the growth of the market. Apart from growth drivers, the report covers the US pediatric cardiology market trends and their foreseeable impact during the forecast period.

The evolution of AI and data science has aided in mechanizing several aspects of medical care such as diagnosis, risk stratification, and management, thus mitigating the burden of physicians and reducing the likelihood of human error. AI modalities have also expanded to the specialty of pediatric cardiology. AI algorithms are being increasingly utilized to analyze complex datasets from imaging studies, such as echocardiograms and cardiac MRIs, enabling early detection of conditions such as congenital heart defects and cardiomyopathies. For instance, research conducted at institutions such as Stanford University has demonstrated the potential of AI to assist in interpreting echocardiographic images, significantly reducing the time required for analysis and improving diagnostic precision which will help in early treatment of pediatric cardiology cases. Furthermore, AI-driven predictive analytics are being applied to assess patient risk factors and outcomes. In addition, ValveTech created a AI integrated minimally invasive heart valve replacement system, designed specifically for pediatric patients, this system adapts to the child's growth, eliminating the need for multiple high-risk surgeries throughout childhood. By leveraging electronic health records, these systems can identify patterns and predict the patients at a higher risk for complications, thus allowing for tailored interventions. For example, a pediatric cardiology unit might use machine learning models to predict which children suffering from congenital heart disease are more likely to require surgery, facilitating proactive management strategies. Additionally, AI is being integrated into remote monitoring technologies, such as wearable devices that track vital signs in real time. This development is particularly beneficial for children suffering from chronic cardiac conditions, as it enables continuous monitoring and timely intervention when abnormalities are detected. Institutions such as Boston Children’s Hospital are exploring these technologies, aiming to enhance patient engagement and self-management. The application of 3D printing, computer modeling, and AI has already led to transformations in procedure planning and physician education in pediatric cardiology. Thus, the integration of AI and machine learning with pediatric cardiology is expected to act as a trend for the growth of the US pediatric cardiology market in the coming years.

The product type segment of the US pediatric cardiology market is segmented into transcatheter heart valves, occlusion devices, atherectomy devices, catheters, stents, introducer sheaths, and others. The catheters segment held the largest market share in 2023. Cardiac catheterization is one of the most widely performed cardiac procedures. Cardiac catheterization can help diagnose and treat different types of congenital and acquired heart conditions. Inoue Balloon Catheter, NC TREK NEO, and Z-Med Catheters are a few of the pediatric cardiac catheters that are used in the US. Hospitals launch various programs to provide technologically advanced catheterization services to treat heart diseases in pediatric patients. For instance, St. Louis Children's Hospital provides a pediatric cardiac catheterization program that includes expert care from doctors, the use of new technology for more accurate treatment and shorter recovery times, and a nationally accredited Catheterization Lab. Similarly, OHSU Doernbecher Children’s Hospital provides a heart catheterization program that helps diagnose and treat complex heart-related conditions without surgery. Thus, the growing number of programs by hospitals to monitor the heart health of children in the US and the increasing use of technologically advanced products for treatment in pediatrics is fueling the growth of the segment.

Based on disease indication, the pediatric cardiology market is segmented into Patent Foramen Ovale, congenital heart disease, acquired heart disease, arrhythmias, cardiomyopathies, and others. The acquired heart disease segment held the largest share of the market in 2023. The acquired heart disease segment is increasingly important in the US pediatric cardiology market as numerous children are being diagnosed with conditions developed postnatally. These conditions include myocarditis, cardiomyopathy, and rheumatic heart disease, and their impact on child health is severe. Advances in diagnostic tools such as echocardiography and cardiac MRI have significantly improved the capability to diagnose these early cases, along with proper intervention and management at the right time. Children's Hospital of Philadelphia and Texas Children's Hospital are developing protocols for the treatment of acquired heart disease as well as introducing specialization in the treatment of acquired heart diseases in children. With growing awareness about acquired heart diseases in children, the need for innovative treatments as well as inclusive long-term care strategies is increasing to achieve better outcomes for the affected children.

Based on surgical procedures, the pediatric cardiology market is segmented into interventional procedures, heart rhythm management procedures, and others. The interventional procedures segment held the largest share of the market in 2023. The interventional procedures segment is likely to grow strongly owing to the development of minimally invasive techniques and an increasing awareness of congenital heart defects in children. A catheter-based intervention for ASD, coarctation of the aorta, and pulmonary valve stenosis, among other conditions, is highly effective and does not require open-heart surgery. Shorter recovery times and less hospitalization are observed with the use of Amplatzer Septal Occluder and balloon dilation catheters. Pediatric cardiology teams are emphasizing training programs and collaborations from multidisciplinary teams to remain updated with the most recent techniques. Interventional procedures significantly improve the quality of care and long-term health outcomes of children suffering from cardiovascular conditions.

By end users, the pediatric cardiology market is categorized into hospitals, specialty clinics, and others. The hospitals segment dominated the market in 2023. In the US pediatric cardiology market, the hospitals segment is significant in terms of delivering specialized care to children suffering from cardiovascular disorders. The increasing cases of congenital heart defects and other heart diseases have elevated pediatric cardiac centers with modern technologies and multidisciplinary teams for comprehensive treatment. Boston Children's Hospital, Texas Children’s Hospital, Seattle Children’s Hospital, and the Children's Hospital of Philadelphia are among the acknowledged leaders, boasting state-of-the-art facilities and innovative approaches to pediatric cardiology—including minimally invasive surgical techniques and interventional procedures. These hospitals emphasize collaborative care, where a cardiologist works with other surgeons, anesthesiologists, and nursing staff to ensure optimized treatment results. Seattle Children’s Hospital performed ~570 pediatric heart surgeries in 2023. Recent investments in telemedicine and remote monitoring technologies further enhance patient management, with constant care and follow-up, highly necessary for patients located in rural areas. Access to specialized care and treatment protocols enhanced in health systems ensures growth in the hospitals segment and advancements in pediatric cardiology, which will improve the quality of life for young patients suffering from cardiovascular problems.

Abbott Laboratories, Medtronic Plc, Edwards Lifesciences Corp, Terumo Corp, W L Gore and Associates Inc, NuMED, Cordis Corp, Occlutech US LLC, Biotronik SE & Co KG, and RENATA MEDICAL are among the leading companies profiled in the US pediatric cardiology market report.  

As per the company news, few of the developments in the market are as follows: 

In August 2024, Renata Medical received the Food and Drug Administration approval for this new Minima stent device that’s specifically tailored for neonates, infants, and young children, but also designed to be re-expanded over the course of their growth period. This approval marks a groundbreaking advancement in the care of young children facing congenital heart defects.
In January 2024, Occlutech received United States Food and Drug Administration (FDA) for Occlutech ASD Occluder and Occlutech Pistol Pusher for the treatment of Atrial Septal Defects (ASD). With this approval, Occlutech will immediately begin commercialization in an exclusive partnership with distributor B. Braun Interventional Systems Inc. (B. Braun Interventional Systems).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com